Cerevast has a deep portfolio of programs applying Transcranial Ultrasound (TUS) and Pulsed Transdermal Electrical Stimulation (pTES) to improve patient care across the heath care continuum. The company’s initial product offerings will target improved sleep, reduced anxiety, stroke treatment and stroke recovery. Additionally, Cerevast is developing microsphere technology for drug delivery and ultrasound-enhanced stroke treatment. These programs coupled with Cerevast’s strong ongoing research and development team uniquely positions the company to expand its portfolio of neurologic products into the future.

Pipeline Image